- Home
- SLGL vs OBIO Comparison
SLGL vs OBIO Comparison
Compare SLGL & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGL | OBIO |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.1M | 246.2M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SLGL | OBIO |
|---|---|---|
| Price | $77.67 | $4.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $110.00 | $14.25 |
| AVG Volume (30 Days) | 50.6K | ★ 121.6K |
| Earning Date | 05-22-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $223.84 | $12.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $0.62 | $2.20 |
| 52 Week High | $97.97 | $5.42 |
Technical Indicators
Market Signals| Indicator | SLGL | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.11 | 41.49 |
| Support Level | $70.31 | $4.02 |
| Resistance Level | $84.75 | $4.17 |
| Average True Range (ATR) | 5.57 | 0.23 |
| MACD | 0.21 | -0.03 |
| Stochastic Oscillator | 55.88 | 12.59 |
Price Performance
Historical ComparisonAbout SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.